Cargando…
Gene Therapy for Lung Diseases
Gene therapy is under development for a variety of lung disease, both those caused by single gene defects, such as cystic fibrosis and α(1)-antitrypsin deficiency, and multifactorial diseases such as cancer, asthma, lung fibrosis, and ARDS. Both viral and nonviral approaches have been explored, the...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7121178/ http://dx.doi.org/10.1007/978-1-59259-963-9_28 |
_version_ | 1783515144519680000 |
---|---|
author | Alton, Eric W.F.W. Davies, Jane C. Geddes, Duncan M. |
author_facet | Alton, Eric W.F.W. Davies, Jane C. Geddes, Duncan M. |
author_sort | Alton, Eric W.F.W. |
collection | PubMed |
description | Gene therapy is under development for a variety of lung disease, both those caused by single gene defects, such as cystic fibrosis and α(1)-antitrypsin deficiency, and multifactorial diseases such as cancer, asthma, lung fibrosis, and ARDS. Both viral and nonviral approaches have been explored, the major limitation to the former being the inability to repeatedly administer, which renders this approach perhaps more applicable to conditions requiring single administration, such as cancer. Progress in development and clinical trials in each of these diseases is reviewed, together with some potential newer approaches for the future. |
format | Online Article Text |
id | pubmed-7121178 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2006 |
record_format | MEDLINE/PubMed |
spelling | pubmed-71211782020-04-06 Gene Therapy for Lung Diseases Alton, Eric W.F.W. Davies, Jane C. Geddes, Duncan M. Principles of Molecular Medicine Article Gene therapy is under development for a variety of lung disease, both those caused by single gene defects, such as cystic fibrosis and α(1)-antitrypsin deficiency, and multifactorial diseases such as cancer, asthma, lung fibrosis, and ARDS. Both viral and nonviral approaches have been explored, the major limitation to the former being the inability to repeatedly administer, which renders this approach perhaps more applicable to conditions requiring single administration, such as cancer. Progress in development and clinical trials in each of these diseases is reviewed, together with some potential newer approaches for the future. 2006 /pmc/articles/PMC7121178/ http://dx.doi.org/10.1007/978-1-59259-963-9_28 Text en © Humana Press Inc. 2006 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Article Alton, Eric W.F.W. Davies, Jane C. Geddes, Duncan M. Gene Therapy for Lung Diseases |
title | Gene Therapy for Lung Diseases |
title_full | Gene Therapy for Lung Diseases |
title_fullStr | Gene Therapy for Lung Diseases |
title_full_unstemmed | Gene Therapy for Lung Diseases |
title_short | Gene Therapy for Lung Diseases |
title_sort | gene therapy for lung diseases |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7121178/ http://dx.doi.org/10.1007/978-1-59259-963-9_28 |
work_keys_str_mv | AT altonericwfw genetherapyforlungdiseases AT daviesjanec genetherapyforlungdiseases AT geddesduncanm genetherapyforlungdiseases |